Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD
NEW ORLEANS — Treatment with survodutide led to significant weight loss and reductions in liver fat in phase III trials of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), but…
